Home Protein Tyrosine Kinase BTK inhibitor Evobrutinib

research use only

Evobrutinib BTK inhibitor

Cat.No.S8777

Evobrutinib is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.
Evobrutinib BTK inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 429.51

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S877701 DMSO]86 mg/mL]false]Ethanol]10 mg/mL]false]Water]Insoluble]false Purity: 99.95%
99.95

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
THP1 Function assay 24 hrs Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay, IC50=0.061μM 32083858
PBMC Function assay 60 mins Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry, IC50=0.061μM 31368705
B cells Function assay 60 mins Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry, IC50=0.32μM 32083858
HEK293 Function assay Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by HPLC analysis, Ki=3.1μM 31368705
Sf21 Function assay Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells, IC50=5.8μM 31368705
BTI-TN-5B1-4 Function assay Covalent binding affinity to human BTK (382 to 659 residues) expressed in baculovirus infected BTI-TN-5B1-4 insect cells by isothermal calorimetry 31368705
Sf21 Function assay 1 uM Inhibition of N-terminal His6-tagged full length human BMX expressed in Sf21 cells at 1 uM 31368705
Sf21 Function assay 1 uM Inhibition of N-terminal His6-tagged human TEC (174 to end aminoacids) expressed in baculovirus infected Sf21 cells at 1 uM 31368705
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 429.51 Formula

C25H27N5O2

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1415823-73-2 -- Storage of Stock Solutions

Synonyms M-2951, MSC-2364447C Smiles C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N

Solubility

In vitro
Batch:

DMSO : 86 mg/mL ( (200.22 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
BTK [1]
(Cell-free assay)
37.9 nM
In vitro

Evobrutinib can inhibit the activity of BTK and prevent the activation of the BCR signaling pathway. It is metabolized via hydroxylation, hydrolysis, O-dealkylation, glucuronidation, and GSH conjugation[2].
In vivo

Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor–mediated signaling.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05248945 Completed
Healthy
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
 January 13 2022 Phase 1
NCT04546789 Completed
Hepatic Impairment
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
 September 30 2020 Phase 1
NCT04314024 Completed
Healthy
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
 May 25 2020 Phase 1
NCT03934502 Completed
Healthy
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
 April 15 2019 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map